-
1 month ago | 
nature.com | Aqeeb ur Rehman |Moazzam Shahzad |Faiz Anwer |Joseph McGuirk |Mohamad Mohty |Nausheen Ahmed | +1 more
AbstractMeasurable residual disease (MRD) testing is emerging as a crucial prognostic and treatment-guiding tool in multiple myeloma (MM). Despite its potential, routine clinical adoption remains inconsistent. This study aimed to explore oncologists’ perspectives on MRD testing and identify barriers and facilitators to its clinical integration. A cross-sectional, modified Delphi survey was conducted among hematologists and oncologists globally, and 115 responses were received.
-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Aug 28, 2024 | 
targetedonc.com | Nausheen Ahmed
A recent study examined the real-world experience of patients receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapies for B-cell non-Hodgkin lymphoma. The primary focus was on the occurrence and duration of side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
-
Aug 27, 2024 | 
onlinelibrary.wiley.com | Utkarsh Goel |Danai Dima |James Davis |Nausheen Ahmed
What is the new aspect of your work? This multicenter retrospective study represents the largest case series describing the use of standard of care chimeric antigen receptor (CAR) T-cell therapy in patients with AL amyloidosis and concurrent relapsed/refractory multiple myeloma. What is the central finding of your work?
-
Aug 15, 2024 | 
targetedonc.com | Nausheen Ahmed
CAR T-cell therapies have shown remarkable efficacy in treating hematologic malignancies but carry risks. Current guidelines require close patient monitoring for 4 weeks post-treatment. A study of 475 patients found that serious side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are extremely rare after 2 weeks.
-
Jul 31, 2024 | 
cancernetwork.com | Nausheen Ahmed
Infection prevention and management is an area that, if addressed, would improve outcomes in patients receiving CAR T-cell therapy, according to Nausheen Ahmed, MD, lead author of a Blood Advances retrospective study. CancerNetwork® spoke with Ahmed, an associate professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center.
-
Jul 31, 2024 | 
cancernetwork.com | Nausheen Ahmed
CancerNetwork® spoke with Nausheen Ahmed, MD, an associate professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center. Ahmed addressed retrospective findings that CAR T-cell therapy may lead to secondary malignancies, and if these findings would influence the use of these agents.
-
Jul 30, 2024 | 
cancernetwork.com | Nausheen Ahmed
CAR T-cell therapy requires a greater investment in a patient’s time and may carry financial and physical burdens from the onset of treatment to weeks upon its completion, according to Nausheen Ahmed, MD. CancerNetwork® spoke with Nausheen Ahmed, MD, an associate professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center.
-
Jul 29, 2024 | 
cancernetwork.com | Nausheen Ahmed
In a conversation with CancerNetwork®, Nausheen Ahmed, MD, spoke about optimizing monitoring strategies for patients with B-cell non-Hodgkin lymphoma who undergo treatment with CAR T-cell therapy.
